Suppr超能文献

急性间歇性卟啉症:聚焦急性和慢性表现的可能机制

Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations.

作者信息

Ma Yuelin, Teng Qing, Zhang Yiran, Zhang Songyun

机构信息

Department of Endocrinology, The second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

School of First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China.

出版信息

Intractable Rare Dis Res. 2020 Nov;9(4):187-195. doi: 10.5582/irdr.2020.03054.

Abstract

Porphyrias are a group of inherited metabolic diseases that include eight types, each of which is caused by a mutation that affects an enzyme of the heme biosynthetic pathway. When an enzyme defect has physiological significance, it leads to overproduction of pathway precursors prior to the defective step. The partial absence of the third enzyme in the heme biosynthetic pathway, porphobilinogen deaminase (PBGD) also known as hydroxymethylbilane synthase (HMBS), results in acute intermittent porphyria (AIP), which affects mainly women. Subjects who had AIP symptoms were deemed to have manifest AIP (MAIP). Clinical manifestations are usually diverse and non-specific. Acute AIP episodes may present with abdominal pain, nausea, and vomiting, and repeated episodes may result in a series of chronic injuries. Therefore, studying the mechanisms of acute and chronic manifestations of AIP is of great significance. This review aims to summarize the possible mechanisms of acute and chronic manifestations in patients with AIP.

摘要

卟啉病是一组遗传性代谢疾病,包括八种类型,每种类型都由影响血红素生物合成途径中一种酶的突变引起。当酶缺陷具有生理意义时,它会导致缺陷步骤之前的途径前体过量产生。血红素生物合成途径中第三种酶卟胆原脱氨酶(PBGD)也称为羟甲基胆色素原合酶(HMBS)部分缺乏,会导致急性间歇性卟啉病(AIP),主要影响女性。有AIP症状的受试者被认为患有显性AIP(MAIP)。临床表现通常多样且不具特异性。急性AIP发作可能表现为腹痛、恶心和呕吐,反复发可能导致一系列慢性损伤。因此,研究AIP急性和慢性表现的机制具有重要意义。本综述旨在总结AIP患者急性和慢性表现的可能机制。

相似文献

1
Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations.
Intractable Rare Dis Res. 2020 Nov;9(4):187-195. doi: 10.5582/irdr.2020.03054.
4
Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
Mol Genet Metab. 2019 Nov;128(3):213-218. doi: 10.1016/j.ymgme.2019.03.002. Epub 2019 Mar 6.
5
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
J Hepatol. 2016 Oct;65(4):776-783. doi: 10.1016/j.jhep.2016.05.012. Epub 2016 May 17.
6
Acute intermittent porphyria: a test of clinical acumen.
J Community Hosp Intern Med Perspect. 2017 Jun 6;7(2):100-102. doi: 10.1080/20009666.2017.1317535. eCollection 2017 Mar.
9
Acute intermittent porphyria caused by novel mutation in HMBS gene, misdiagnosed as cholecystitis.
Neuropsychiatr Dis Treat. 2014 Nov 12;10:2135-7. doi: 10.2147/NDT.S73070. eCollection 2014.

引用本文的文献

1
A New Generation of Porphyrias: A Case of Acute Intermittent Porphyria.
Cureus. 2025 Mar 14;17(3):e80552. doi: 10.7759/cureus.80552. eCollection 2025 Mar.
2
An easily overlooked disease in the early stages: acute intermittent porphyria.
BMC Neurol. 2025 Feb 13;25(1):61. doi: 10.1186/s12883-025-04064-0.
3
Human Chorionic Gonadotropin (hCG) Injections Exacerbating Acute Intermittent Porphyria in a 34-Year-Old Woman.
Cureus. 2024 Sep 4;16(9):e68651. doi: 10.7759/cureus.68651. eCollection 2024 Sep.
6
A case report of acute intermittent porphyria leading to severe disability.
Front Neurol. 2024 Jan 11;14:1334743. doi: 10.3389/fneur.2023.1334743. eCollection 2023.
8
Acute Intermittent Porphyria's Symptoms and Management: A Narrative Review.
Cureus. 2023 Mar 13;15(3):e36058. doi: 10.7759/cureus.36058. eCollection 2023 Mar.
9
Novel gene mutation identified and confirmed in a woman with acute intermittent porphyria: A case report.
World J Clin Cases. 2022 Nov 26;10(33):12319-12327. doi: 10.12998/wjcc.v10.i33.12319.
10
Inferior Vena Cava Thrombosis in a Porphyria Patient.
Acta Cardiol Sin. 2022 Nov;38(6):802-805. doi: 10.6515/ACS.202211_38(6).20220603B.

本文引用的文献

2
Acute Intermittent Porphyria: Current Perspectives And Case Presentation.
Ther Clin Risk Manag. 2019 Dec 16;15:1443-1451. doi: 10.2147/TCRM.S180161. eCollection 2019.
3
Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families.
Ann Hematol. 2019 Dec;98(12):2683-2691. doi: 10.1007/s00277-019-03831-7. Epub 2019 Nov 19.
4
Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction.
Mol Genet Metab. 2019 Nov;128(3):242-253. doi: 10.1016/j.ymgme.2019.10.011. Epub 2019 Nov 1.
5
Neurological and neuropsychiatric manifestations of porphyria.
Int J Neurosci. 2019 Dec;129(12):1226-1233. doi: 10.1080/00207454.2019.1655014. Epub 2019 Sep 1.
6
Acute hepatic porphyrias: Current diagnosis & management.
Mol Genet Metab. 2019 Nov;128(3):219-227. doi: 10.1016/j.ymgme.2019.07.002. Epub 2019 Jul 5.
7
A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.
Scand J Clin Lab Invest. 2019 Sep;79(5):305-313. doi: 10.1080/00365513.2019.1622030. Epub 2019 Jun 1.
8
Clinical Guide and Update on Porphyrias.
Gastroenterology. 2019 Aug;157(2):365-381.e4. doi: 10.1053/j.gastro.2019.04.050. Epub 2019 May 11.
9
Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
Mol Genet Metab. 2019 Nov;128(3):213-218. doi: 10.1016/j.ymgme.2019.03.002. Epub 2019 Mar 6.
10
Acute Hepatic Porphyrias: Review and Recent Progress.
Hepatol Commun. 2018 Dec 20;3(2):193-206. doi: 10.1002/hep4.1297. eCollection 2019 Feb.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验